Sign in
BIAF Stock Price, Chart, Stats & News
bioAffinity Technologies, Inc.
Save
3.72M
Market cap
–
Current P/E
–
Forward P/E
BIAF chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 23.21% |
Operating margin | -171.58% |
Pretax margin | -241.25% |
Net margin | -241.96% |
Effective tax rate | -0.30% |
ROA | -136.03% |
ROE | -385.19% |
D/E | 0.16x |
Interest coverage ratio | -238.27x |
BIAF valuation
P/E | – |
P/S | 2.92x |
P/B | 0.95x |
P/CF | -0.74x |
P/FCF | -1.93x |
P/OCF | -0.74x |
PEG | -0.02x |
EV multiple | -1.62x |
About
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level.
Similar securities
Based on sector and market capitalization
Report issue